A Phase 1 interventional study of AZD9668 and Warfarin in Pharmacokinetics and Pharmacodynamics, sponsored by AstraZeneca. Withdrawn at 2 sites in Sweden. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-29.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to determine whether the treatment with AZD9668 will affect the metabolism and effect of Warfarin.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD9668 - 2 x30mg tablets
Drug: AZD9668
Warfarin - 10 x2.5 mg tablets
Drug: Warfarin
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 1
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 2
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 3
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 4
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 5
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 6
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 7
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 8
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 9
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 10
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 11
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 12
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 13
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 14
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 15
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 16
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 17
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 18
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 19
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 20
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 21
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 22
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Time frame: Pharmacokinetic (PK) sampling will be performed day 23
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 1
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 2
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 3
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 4
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 5
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 6
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 7
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 8
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 9
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 10
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 11
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 12
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 13
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 14
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 15
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 16
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 17
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 18
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 19
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 20
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 21
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 22
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Time frame: International normalised ratio (INR) sampling will be performed day 23
Pharmacokinetics for AZD9668 measured by Css,max
Time frame: Range from day 9 to 23
Pharmacokinetics for AZD9668 measured by tss,max
Time frame: Range from day 9 to 23
Pharmacokinetics for AZD9668 measured by Css,min
Time frame: Range from day 9 to 23
Pharmacokinetics for AZD9668 measured by CLss/F
Time frame: Range from day 9 to 23
Severity of Adverse Events as a Measure of Safety and Tolerability
Time frame: Adverse events will be collected pre-dose, during treatment and at follow up
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time frame: Adverse events will be collected pre-dose, during treatment and at follow up
Pharmacokinetics for (R)- and (S)- Warfarin measured tmax.
Time frame: Range from day 1 to 23
Pharmacokinetics for (R)- and (S)- Warfarin measured t½.
Time frame: Range from day 1 to 23
Pharmacokinetics for (R)- and (S)- Warfarin measured CL/F.
Time frame: Range from day 1 to 23
Pharmacokinetics for (R)- and (S)- Warfarin measured Vz/F.
Time frame: Range from day 1 to 23
The record gives a start of Nov 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alvelestat · Warfarin